Otros idiomas Ionis Pharmaceuticals, Inc.

Acciones

IONS

US4622221004

Biotecnología e investigación médica

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 13/05/2026			Variación 5 días	Varia. 1 de enero.
77,60 ^USD	+2,33 %		+0,98 %	-1,91 %

12/05	Ionis Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 10:40 AM
30/04	IONIS PHARMACEUTICALS, INC. : recomendación de compra de RBC Capital Markets	ZM

Otros idiomas

04/05	Ionis to host 2026 virtual Annual Meeting of Stockholders
01/05	Ionis to present at upcoming investor conferences
29/04	Ionis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
29/04	Ionis Pharmaceuticals Q1 Net Loss Narrows, Revenue Increases; Lifts 2026 Revenue Guidance
29/04	Ionis Pharmaceuticals : Q1 2026 Ionis Earnings Slides
29/04	(IONS) Ionis Pharmaceuticals Expects 2026 Total Revenue Range $875M - $900M, vs. FactSet Est of $808.5M
29/04	Earnings Flash (IONS) Ionis Pharmaceuticals Posts Q1 Loss $0.56 a Share, vs. FactSet Est of $0.88 Loss
29/04	Earnings Flash (IONS) Ionis Pharmaceuticals, Inc. Reports Q1 Revenue $246.0M, vs. FactSet Est of $195.6M
29/04	Ionis Pharmaceuticals: Q1 Earnings Snapshot
29/04	Ionis reports first quarter 2026 financial results and highlights progress on key programs
29/04	Ionis Pharmaceuticals, Inc. Revises Earning Guidance for the Year 2026
28/04	Ionis Pharmaceuticals Says FDA Grants Priority Review for Potential Chronic Hepatitis B Treatment
28/04	Ionis partner GSK says FDA grants Priority Review, breakthrough status to hepatitis B drug bepirovirsen
28/04	Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
28/04	Ionis Pharmaceuticals, Inc. Partner GSK Announces Bepirovirsen Accepted For Priority Review And Granted Breakthrough Therapy Designation By U.S. FDA As A Potential First-In-Class Medicine For Chronic Hepatitis B
28/04	GSK plc Announces Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by the US FDA
27/04	Intellia's gene therapy for rare disease cuts swelling attacks in late-stage trial
21/04	Ionis Pharmaceuticals Reports Significant Results for Zilganersen in Alexander Disease Trial
21/04	Ionis Pharmaceuticals Inc - Zilganersen 50 mg meets primary endpoint, stabilizes gait speed in patients ≥5 years at week 61
21/04	Ionis Pharmaceuticals Inc Presents New Data from Pivotal Study of Zilganersen in Alexander Disease
21/04	Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
21/04	Analyst recommendations: Colgate-Palmolive, Intel, Netflix, Spotify, Dell…
15/04	Ionis to hold first quarter 2026 financial results webcast
09/04	Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says
06/04	Praxis Precision Medicines Announces Positive Results From The Embrave Part A Trial Of Elsunersen In Patients With Scn2a Early-Onset Developmental And Epileptic Encephalopathy